Neuro Immunoassay Market

By Technology;

Radioimmunoassays (RIA), Polymerase Chain Reaction (PCR), ELISA, Western Blot, Rapid Tests, and ELISPOT

By Product;

Reagents & Kits and Analysers

By Application;

Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, ALS, and Spinal Muscular Atrophy (SMA)

By End User;

Hospitals, Clinics, Academic Organizations, Biopharmaceutical Companies, Pharmaceutical Companies, and Others

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn608823824 Published Date: August, 2025 Updated Date: September, 2025

Neuro Immunoassay Market Overview

Neuro Immunoassay Market (USD Million)

Neuro Immunoassay Market was valued at USD 2,881.51 million in the year 2024. The size of this market is expected to increase to USD 4,867.46 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 7.8%.


Neuro Immunoassay Market

*Market size in USD million

CAGR 7.8 %


Study Period2025 - 2031
Base Year2024
CAGR (%)7.8 %
Market Size (2024)USD 2,881.51 Million
Market Size (2031)USD 4,867.46 Million
Market ConcentrationMedium
Report Pages369
2,881.51
2024
4,867.46
2031

Major Players

  • Intrinsic LifeSciences
  • Danaher Corporation
  • Becton Dickinson and Company
  • Akers Biosciences, Inc
  • Abbott Laboratories
  • EDP Biotech Corporation

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Neuro Immunoassay Market

Fragmented - Highly competitive market without dominant players


The Neuro Immunoassay Market is growing notably, with demand rising by over 40% due to an increase in neurodegenerative and autoimmune disorders. Providers are increasingly relying on immunoassay platforms for early disease detection and monitoring. Companies are executing clear strategies to deploy reagent kits and instruments across hospitals and research labs. Strong collaboration between diagnostic innovators and neuroscience centers is supporting sustained market expansion.

Strategic Collaborations Powering Market Access
Over 38% of new assay solutions are introduced via strategic collaborations among biotech firms, diagnostics manufacturers and academic labs. These alliances streamline regulatory pathways and strengthen credibility. Mergers and joint ventures expand distribution channels and broaden access to diagnostic platforms. These collaborative networks underpin consistent market growth.

Wider Adoption Across Clinical and Research Settings
Adoption of neuro immunoassay solutions has increased by more than 42% across hospital labs, clinical trial networks,and pharma development centers. Providers are integrating these assays into screening, monitoring, and research workflows. Companies pursue comprehensive growth strategies like bundled instrument kits, training modules and service contracts. Collaborating with health systems enhances accessibility and supports scalable expansion.

Future Outlook Focused on Smart, Multiplex Platforms
More than 44% of upcoming platforms feature multiplex detection, digital connectivity and real‑time analysis—defining the market’s future outlook. These systems support personalized diagnostics and integration with digital health tools. Ongoing innovation in predictive analytics and cloud reporting, coupled with extensive collaboration, is shaping next‑generation immunoassay solutions and long‑term expansion.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Technology
    2. Market Snapshot, By Product
    3. Market Snapshot, By Application
    4. Market Snapshot, By End User
    5. Market Snapshot, By Region
  4. Neuro Immunoassay Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Rising incidence of neurological diseases
        2. Increasing investment in neuroscience research
        3. Technological advancements
      2. Restraints
        1. High cost of neuro immunoassays
        2. Lack of skilled personnel
        3. Stringent regulatory requirements
      3. Opportunities
        1. Emerging markets
        2. Point-of-care testing
        3. Companion diagnostics
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry

  5. Market Segmentation
    1. Neuro Immunoassay Market, By Technology, 2021 - 2031 (USD Million)
      1. Radioimmunoassays (RIA)
      2. Polymerase Chain Reaction (PCR)
      3. ELISA
      4. Western Blot
      5. Rapid Tests
      6. ELISPOT
    2. Neuro Immunoassay Market, By Product, 2021 - 2031 (USD Million)
      1. Reagents and Kits
      2. Analysers
    3. Neuro Immunoassay Market, By Application, 2021 - 2031 (USD Million)
      1. Alzheimer’s Disease
      2. Parkinson’s Disease
      3. Huntington’s Disease
      4. ALS
      5. Spinal Muscular Atrophy (SMA)
    4. Neuro Immunoassay Market, By End User, 2021 - 2031 (USD Million)
      1. Hospitals
      2. Clinics
      3. Academic Organizations
      4. Biopharmaceutical Companies
      5. Pharmaceutical Companies
      6. Others
    5. Neuro Immunoassay Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Intrinsic LifeSciences
      2. Danaher Corporation
      3. Becton Dickinson and Company
      4. Akers Biosciences, Inc
      5. Abbott Laboratories, Inc
      6. EDP Biotech Corporation
  7. Analyst Views
  8. Future Outlook of the Market